tions; their use can cause disequilibrium between intracellular/extracellular sodium and water concentrations, which in children has caused fits and permanent neurological damage (Morris-Jones et al. 1967).
Case report
A 32-year-old man presented in April 1982 with a pigmented nodular lesion in the right scapular region, present for three years. A malignant melanoma was diagnosed and histology confirmed a tumour measuring 4.5 mm in thickness and penetrating into the reticular dermis (Clark's level IV). The lesion was widely excised and the defect covered with a skin graft. At the same time a palpable lymph node in the right axilla was biopsied but this showed reactive changes only.
The patient remained well until April 1983 when he had a small haemoptysis; fibreoptic bronchoscopy showed a large tumour mass virtually occluding the right main bronchus. A biopsy of this mass showed metastatic malignant melanoma. A few days later the patient had a grand mal seizure. A CAT scan of the brain showed a metastasis in the left posterior parietal region enhancing with contrast and surrounded by considerable oedema (Figure 1) .
Treatment was initiated with oral chemotherapy with CCNU, dibromodulcitol and hydroxyurea (CDH), followed by whole-brain irradiation. He continued cyclical chemotherapy with the DPV3 regimen which incorporates vinblastine, cisplatin and vindesine alternating with dacarbazine and vincristine (Retsas & Nicoll 1984) . A repeat CAT scan of brain in October 1983 showed almost complete regression of tumour (Figure 1) .
By November 1984, 18 months after his presentation with pulmonary and cerebral metastases, the patient had no evidence of recurrence; he had been back at work during the previous year and remained on maintenance oral chemotherapy.
Discussion
The prognosis of patients with disseminated malignant melanoma remains poor. However, approximately 30% of patients treated with chemotherapy for surgically incurable metastatic disease will experience an objective tumour regression and a clinical remission lasting on average 9 months to one year. Recent analysis of survival data from 240 patients treated with three different chemotherapy regimens at Westminster Hospital revealed that 25 patients (10%) survived longer than 2 years following response to treatment (Retsas et al. 1985) ; the longest survivor of these remains in unmaintained clinical remission at 83 months. From a subgroup of 100 patients with cerebral involvement, 10 experienced an objective regression of cerebral lesions following treatment and 5 of these survived longer than one year, the longest survivor from this subgroup remaining in clinical remission for 65 months. In contrast, the median survival of patients with cerebral metastases unresponsive to treatment is lmiited to less than three months. Patients with widely disseminated metastatic melanoma should be informed of the available therapeutic options, particularly as at present it is not possible to predict those who are likely to respond to treatment.
Addendum: Two weeks after this patient was presented at the RSM he had a grand mal epileptic attack. A CAT scan of the brain repeated on 19 December 1984 showed a small lesion of mixed attenuation in the left parietal lobe, the site of the previously documented metastasis, which showed some enhancement after intravenous contrast. Subsequent scans confirmed the presence of new cerebral metastases, from which the patient died on 25 June 1985.
